CPT code 55712 denotes a transperineal prostate biopsy performed with MRI–ultrasound fusion targeting a single suspicious lesion. The code captures the initial targeted-lesion sampling and is used in settings where MRI findings guide biopsy to improve detection of clinically significant prostate cancer. Nationally, use of image-fusion targeted biopsy has grown as MRI becomes more integrated into prostate cancer diagnostic pathways, making accurate coding for targeted procedures increasingly important for clinical documentation and claims processing.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical procedure and typical sites of service, along with what to expect from coding and billing perspectives when this code is used. The publication outlines benchmark considerations, common related services, and policy developments affecting image-guided prostate biopsy coding and coverage. It also provides clinical context about why MRI–ultrasound fusion targeting matters for diagnostic accuracy and how CPT code 55712 fits into broader prostate biopsy coding schemes.

Data not available in the input for payer-specific rates, modifiers, taxonomies, ICD-10 pairings, and related codes.